过滤器使用后: #Aldevron 全年 2019 所有 EQT AB Group 所有基金 所有公司 EQT Credit Opportunities III EQT Infrastructure III EQT Infrastructure IV EQT Mid Market Asia III EQT Mid Market Europe EQT Mid Market US EQT Mid-Market Credit EQT Mid-Market Credit II EQT Real Estate I EQT Ventures EQT Ventures II EQT VIII 殷拓VI 殷拓VII 殷拓大中华 II 殷拓基建II 殷拓拓展 II 殷拓信贷 II 殷拓中型市场 Acumatica Adamo Aldevron Allee Center Anticimex Apleona Artwall Atricom and Le Büro Azelis Banking Circle BBS Automation BBS Automation Biovian Biovian Bluestep Bank Cast & Crew Castle Certara China Shine Clinical Innovations Clinical Innovations Curaeos Data Intensity Dataflow Dellner Couplers DeltaFiber NL Desotec Direct ChassisLink Direct ChassisLink Dorner Dunlop ELEVATE Ellab Epidemic Sound Eton Facile Fenix Marine Services Fertin Pharma Flying Tiger Copenhagen FocusVision Galderma GETEC GlobalConnect GPA Global Hector Rail HusCompagniet HyTest HyTest IFS Igenomix ILA Vietnam In.Corp Group Independent Vetcare Limited inexio Innovyze IP-Only Iver Karo Pharma kfzteile24 Kodiak Gas Services, LLC Kuoni Group / VFS Global Lima Maria MediFox MediFox Melita Metalcaucho Metalcaucho MHC Asia Musti ja Mirri Nest Nexon Asia Pacific Nordic Aviation Capital Open Systems Osmose Utilities Services, Inc. Ottobock Paymentsense Paymentsense Qinterra SAUR SAUR SEGRA Sitecore Sivantos Sivantos(2) Sivantos(3) Sivantos(3)(2) Smart Parc Southside Stendörren StormGeo SUSE Synagro TIA Technology Touhula Unilode Aviation Solutions Unum Utimaco VBill Veritas Petroleum Services (VPS) Veritas Petroleum Services (VPS) WASH Waystar Zemax 英莳国际 长水教育集团 中国连锁餐饮集团 所有 殷拓新闻稿 Regulatory Press Releases 殷拓近报 过滤器 EQT to acquire majority interest in Aldevron – the leading global supplier of plasmid DNA used in cell and gene therapies 31 七月 2019 #新闻稿 #EQT VIII #Aldevron #US EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey EQT will support Aldevron through investments in additional production capacity, R&D, and growth initiatives and by leveraging EQT’s strong healthcare expertise, global...
EQT to acquire majority interest in Aldevron – the leading global supplier of plasmid DNA used in cell and gene therapies 31 七月 2019 #新闻稿 #EQT VIII #Aldevron #US EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey EQT will support Aldevron through investments in additional production capacity, R&D, and growth initiatives and by leveraging EQT’s strong healthcare expertise, global...
